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cancer (-54%), CIN1 (-71%), CIN2/3 (-70%), genital warts among females (-75%) and 
males (-63%), and cervical cancer deaths (-52%). Routine vaccination also resulted in 
reduction of disease costs for cervical cancer (-24%), CIN1 (-42), CIN2/3 (-41%), genital 
warts in females (-52%) and males (-42%). The reduction in HPV6/11-related disease 
incidence and costs avoided occurred relatively soon after vaccination, especially 
CIN1 and genital warts. Considering the recommended threshold of 160,000 THB/
QALY, both routine and routine plus catch-up programs are cost-effective with dis-
counted incremental cost-effectiveness ratios (ICER) of 35,124 and 34,426 THB/QALY, 
respectively. The ICER increased by about 31% for both strategies when HPV6/11-
related effects were excluded. ConClusions: The school-based HPV vaccination 
program, using the quadrivalent HPV vaccine, is cost-effective, particularly when 
catch-up vaccination is incorporated. The results support decision-making process 
to include HPV vaccination in Thailand NIP.
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Cost-Utility ANAlysis of first-liNe regimeN BetweeN CisPlAtiN PlUs 
Pemetrexed ANd CArBoPlAtiN PlUs PAClitAxel iN AdvANCed NoN-
sqUAmoUs NoN-smAll-Cell lUNg CANCer iN thAilANd
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objeCtives: Cisplatin plus pemetrexed (Cis/Pem) is a more costly chemotherapy 
regimen than carboplatin plus paclitaxel (Carb/Pac), but with the reports about its 
higher efficacy and less toxicity. Thus, this study aimed to assess the cost-utility 
of these two chemotherapy regimens in advanced non-squamous non-small cell 
lung cancer (NSCLC) in Thailand. Methods: Economic study was conducted along 
a prospective cohort study in Maharaj Nakorn Chiang Mai hospital located in the 
north of Thailand. Patients aged 18 or above, diagnosed with non-squamous NSCLC 
with stage IIIB and IV, had performance status (ECOG) 0-1, and were treated either 
Cis/Pem or Carb/Pac was enrolled during January 2012 to June 2013. Direct and 
indirect costs were collected considering the societal perspective. Effectiveness was 
measured in terms on time days to disease progression. The incremental cost per 
quality-adjusted time to disease progression was calculated. A series of sensitiv-
ity analyses were also performed. Results: Of the total 54 patients, 36 received 
Carb/Pac and the remaining received Cis/Pem. Median time to disease progression 
was 119.94 days and 100.17 days for patients who received Cis/Pem and Carb/Pac 
respectively. Cis/Pem regimen had a higher total cost of 463,678 Bath per case while 
gained 15.95 quality adjusted-day to progression compared with Carb/Pac regimen. 
The resulted in 29,078.92 Baht per quality adjusted time day to progression per 
patient. ConClusions: Our findings suggested that Cis/Pem regimen gains slightly 
more effectiveness than Carb/Pac regimen with rising additional cost incurred. 
However, in cancer treatment, selection the appropriate treatment to individual 
patients might need to consider other issues such as quality of life. Beyond only 
health care resources.
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objeCtives: Abraxane® and Taxol® are both effective agents for the treatment of 
advanced stage breast cancer. However, each agent possesses unique drug delivery 
characteristics with the former not requiring premedication and having a consider-
ably shorter recommended infusion time (i.e. 30 min vs. 2 - 4 hours). To measure the 
overall efficiency and cost saving potential associated with Abraxane® relative to 
Taxol®, a time and motion study was undertaken in breast cancer patients treated 
in China. Methods: Baseline data collection included patient and disease charac-
teristics. Time and resource use data were then collected from breast patients being 
treated with Abraxane® (n= 12) or Taxol® (n= 15) in one of three cancer clinics located 
in Jiangsu, Shanghai and Beijing. Resource use and time impact on clinical staff 
were quantified using unit cost estimates. This included costs for drug preparation, 
administration, materials and supplies, premedication, patient chair time, labor 
costs and all acute adverse drug reactions. All costs were reported in $U.S. (1$U.S. = 
6.1 RMB). Results: Approximately 9 of 12 (75%) patients received Abraxane® as on 
a weekly schedule compared to 6 of 15 (40%) with Taxol®. There were 5 (33.3%) acute 
adverse drug reactions with Taxol®, 3 of which required a physician visit and the 
initiation of supportive interventions. In contrast, there was only one minor event 
with Abraxane® (8.3%), which was easily managed with a temporary stoppage of the 
infusion. From the time and motion study, the mean total time for Abraxane® and 
Taxol® delivery was 84 and 282 minutes (p < 0.001), with the associated costs being 
$59 and $254 respectively per dose (p < 0.001). ConClusions: To our knowledge, 
this is first such study in breast cancer patients undertaken in China. Abraxane® 
was associated with fewer acute adverse drug reactions and significant reductions 
in health care resources, physician/nurse time and overall drug delivery costs com-
pared to Taxol®.
CANCer – Patient-reported outcomes & Patient Preference studies
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objeCtives: The aim of the study was to explore knowledge on HPV, and to learn 
about women’s attitudes to vaccination in Hungary. Methods: A quantitative cross-
sectional study was performed among the mothers of girl students in a public edu-
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objeCtives: To evaluate the health and economic benefits of different screening 
and vaccination strategies against cervical cancer in the Philippines. Methods: A 
cost-utility analysis was conducted using an existing semi-Markov model to evalu-
ate different screening (i.e. Pap smear, visual acetic acid) and vaccination strategies 
against HPV infection implemented alone or as part of a combination strategy at 
different coverage scenarios. From a health system perspective, the researchers 
ran the model using country-specific epidemiologic, cost and clinical parameters. 
Sensitivity analysis was performed for vaccine efficacy, duration of protection and 
costs of vaccination, screening and treatment. Results: Across all coverage sce-
narios, VIA has been shown to be a dominant and cost-saving strategy with ICERs 
ranging from -Php 191,099 to Php 61,058.73 per QALY gained. Due to its high cost in 
the Philippines, Pap smear was found to be not cost-effective. At a cost of Php 2,400 
per vaccinated girl, vaccination was found to be cost-effective at a threshold of 1 
GDP per capita with the most favorable assumption of providing lifelong immunity 
against high-risk oncogenic HPV types 16/18. The highest incremental QALY gain 
was achieved with 80% coverage of the combined strategy of VIA at 35 to 45 years 
old done every five years following vaccination at 11 years of age with an ICER of 
Php 33,126. HPV vaccination becomes less cost-effective when vaccine protection 
lasts for less than 15 years. ConClusions: High VIA coverage targeting women 
aged 35-45 years old at five-year intervals is the most efficient and cost-saving 
strategy in reducing cervical cancer burden in the Philippines. Adding a vaccina-
tion program among 11-year old girls at a cost of Php 2,400 per vaccinated child is 
potentially cost-effective with the most favourable assumption that the vaccines 
provide lifelong immunity against HPV 16/18.
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objeCtives: Cancer therapy has been revolutionized by the introduction of tar-
geted therapy. Tremendous growth of its utilization was observed in Singapore over 
the past decade. Despite high treatment cost, most of the targeted therapies were 
not funded by Singapore’s unique health care financing system. Hence, this study 
aims to determine the trends of use of targeted therapy in National Cancer Centre 
Singapore from 2007-2011. In addition, treatment response and economic evalua-
tion of Gefitinib as a first line therapy for advanced NSCLC will be conducted to aid 
decision making. Methods: In this retrospective study, number of patients and 
annual consumption costs for each targeted therapy were determined. A total of 124 
chemo naive patients were identified to examine treatment response and resources 
used for Gefitinib. These were reviewed via electronic databases and medical reports. 
A Markov model was developed by using patient level data and utility values from 
literature. Cost utility analysis was performed from health care provider’s perspec-
tive with inclusion of direct medical costs (2012 Singapore dollars) and discount 
rate of 3%. Results: Dominant trends were observed in utilization of Trastuzumab 
(35%), Gefitinib (25%) and Bevacizumab (12%) over last 5 years. For Gefitinib, partial 
response and stable disease were 23.4% and 64.5% respectively. It resulted in a gain 
of 73.23 progression free days and 2.87 quality adjusted life year (QALY) with an 
additional cost of S$30,819.28. As a result, incremental cost-utility ratio (ICUR) of 
Gefitinib is S$10,749.86 per QALY and it was most sensitive to the cost of Gefitinib 
in one way sensitivity analysis. ConClusions: Top three drugs with high utiliza-
tion and consumption costs were Trastuzumab, Gefitinib and Bevacizumab. If the 
acceptable ICUR threshold in Singapore is 1 to 3 times of gross domestic product 
range, Gefitinib can be considered cost-effective compared to chemotherapy as first 
line treatment of NSCLC for local population.
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objeCtives: This study estimated health impact and cost-effectiveness of adding 
a quadrivalent HPV vaccination program for preadolescent girls to the existing 
cervical cancer screening program from the Thai payer perspective. Methods: A 
published transmission-dynamic model was adapted to Thailand setting. Both direct 
and indirect (herd immunity) benefits were captured by the model. Model inputs 
were obtained from literature, unpublished data and expert opinion. A proposed 
tender price of vaccine shown on recent news plus logistics, management and 
administration costs were used as vaccine-related costs to reflect the real situa-
tion of Thailand school-based HPV vaccination. Future costs and outcomes were 
discounted at 3%. Two vaccination strategies of combining cervical cancer screening 
with routine vaccination (11- to 12-year-old females) and with routine plus 5-year 
catch-up vaccination (13- to 24-year-old females) were compared to screening pro-
gram alone. Results: Adding HPV vaccination to the screening program provided 
both short- and long-term health benefits. Compared with current screening prac-
tice over 100 years, routine vaccination reduced cumulative incidence of cervical 
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pain, the distress caused by the pain and the pain’s experience are affected by many 
factors and these factors should be considered during the multidisciplinary care. We 
supposed that in case of hospice patients the circumstances, the place of the care 
and family support are such significant factors. Our aim was to compare hospice 
patients cared by home-hospice service and hospice department regarding pain and 
functional capabilityin Hungary. Methods: A quantitative crossectional study was 
performed in 2011-2012 using an anonymous questionnaire. Our tool contained a 
visual analog scale (VAS) to measure the intensity of pain, Beck depression inventory 
SF and self-developed questions. SPSS.18.0. programme was used for data analysis, 
regression analysis, khi-square, Mann-Whitney and Kruskal-Wallis tests were used to 
find out the correlations. Finally 120 patients (n= 120) participated in our study from 
the Southern Transdanubian region of Hungary. Results: The total intensity of pain 
was 4,4 ± 2,2 at the hospice department and 2,4 ± 0,9 in case of home hospice patients. 
There was a significant difference between the two groups (p< 0,001). We found signifi-
cant correlation regarding the intensity of pain and severity of depression (p< 0,001). 
The presence of pain affected the functional capability, the decrease of the capability 
was connected with the increase of the pain. ConClusions: We concluded that the 
place of the care is a determinative factor in case of hospice patient care. Part of the 
patient centralized care we have to focus on the family support and one of our chal-
lenge should be to teach the family how to care their relatives. With the enhance of 
the family care it is possible to fill the health care system’s gaps in.
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objeCtives: The objectives of the study were to assess the quality of life (QOL) 
among patients with esophageal/cardiac precursor lesion or cancer at differ-
ent stages, and evaluate changes in QOL during follow-up after primary treat-
ment. Methods: We enrolled 220 patients with esophageal or cardiac lesion 
between September 2007 and January 2010. They were followed up with the 
EuroQol-5 dimension (EQ-5D) for QOL before primary treatment and at 1, 6 and 
12 months after primary treatment. We calculated QOL scores (in terms of EQ-5D 
scores) based on the five-item descriptive system of health states of the EQ-5D and 
the UK preference weighting system. Results: In total, 74 patients with precancer-
ous lesion, 88 with early stage cancer, and 58 with advanced cancer participated 
in our survey. Prior to clinical treatment, the average EQ-5D score of patients with 
advanced cancer was 0.81±0.17 (mean ± standard deviation), significantly lower 
than that of patients with early stage cancer (0.87±0.09) or precancerous lesion 
(0.90±0.05) (P< 0.01). For precursor lesion, the score declined in the first month 
(P< 0.001), and gradually increased to a higher level at 12 months than before treat-
ment (P= 0.023). It showed a similar trend for early cancer (P< 0.05), though it was 
not statistically recovered even at 12 months (0.85±0.15 versus 0.87±0.09, P= 0.226). 
Regarding advanced cancer, the score showed a consistent decline, reached the 
lowest at 6 month, and finally rebounded to a similar level compared to that before 
treatment (0.80±0.13 versus 0.81±0.17, P= 0.624). ConClusions: Our results indicate 
that patients with precursor lesion or early stage esophageal or cardiac cancer have 
better QOL than do those with advanced cancer. Early detection and treatment 
improve QOL in the long run, despite QOL compromise in the immediate time. 
Particular attention and extra care should be given in the early period of treatment 
for patients.
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objeCtives: To develop an algorithm mapping the Functional Assessment of 
Cancer Therapy – Breast (FACT-B), to the 5-level EuroQoL Group’s 5-dimension 
questionnaire (EQ-5D-5L) index. Methods: A baseline survey of 238 self-admin-
istered breast cancer patients in Singapore was conducted. Regression models using 
ordinary least square, Tobit and censored least absolute deviation were fitted to 
predict the EQ-5D-5L index based on the five subscale (physical, social/family, emo-
tional, functional well-beings, additional concerns for breast cancer) scores of the 
FACT-B. Data from a follow-up survey of these patients were used to validate the 
results. Results: A model that maps the physical, emotional, function well-being 
subscales and the breast cancer concerns of the FACT-B to the EQ-5D-5L index was 
derived. The social/family well-being subscale was not associated to the EQ-5D-5L 
index. Although theoretic assumptions may not hold, ordinary least square showed 
better goodness-of-fit measures than other regression methods. The mean predicted 
EQ-5D-5L index within each performance status level deviated from the observed 
mean. However, the magnitudes of the deviations were smaller than the minimally 
important difference in EQ-5D for cancer patients. ConClusions: The mapping 
algorithm converts the FACT-B to the EQ-5D-5L index, which is essential in health 
economic evaluation. This enables oncologists and clinical researchers to obtain 
a quantitative utility summary of a patient’s health status when only the FACT-B 
is assessed.
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objeCtives: Report of health-related quality of life (HRQOL) among cervical cancer 
patients in Indonesia is very rare. This study aimed to examine the HRQOL of cervi-
cal cancer patients in Indonesia using EQ-5D-3L. Methods: A cross-sectional sur-
cational institution of Nagyatád town by a self-edited questionnaire. Women with 
an address in the city of Nagyatád and each having a 9-14-year-old daughter were 
chosen for the study. 247 questionaire were distributed and 186 were returned for 
evaluation. The study was performed in 2012. Results: 84.4% of the women knew the 
meaning of the acronym of HPV. Women living in marriage or cohabitation (χ 2= 5,966, 
p= 0,015), and with income above average (χ 2= 5,643, p= 0,018) were significantly better 
informed on HPV than single mothers. Only 26.9% of the women knew the role of the 
virus played in lip and oral cavity cancer, and 38.7% of them described the possibility 
of the infection in men. As a conclusion, 17.2% of 186 women gave correct answers 
on HPV. Significantly increased awareness proved to be for 38- year -old or older 
women of higher level education, or in intellectual work (p< 0,05). ConClusions: 
Despite Nagyatád women provided greater awareness on HPV causing cervical cancer 
compared to data in the literature, their overall knowledge on HPV is modest. In the 
future, a wide range of information should be provided for them.
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objeCtives: The use of cost-effectiveness and valuation of the inherent value 
of health care interventions has been growing in Asia. To understand the think-
ing of subjects responding to a time-trade-off and willingness-to-pay assess-
ment, subjects were asked to describe what they considered when making their 
evaluation. Understanding their rationale will provide insights into the values of 
respondents. Methods: Data were collected from 300 respondents (150 lung can-
cer patients; 150 general public). Subjects responded to hypothetical lung cancer 
health states, described by three levels of severity and two levels of side-effects, and 
provided their valuation of their utility through a visual analog scale and time-trade-
off and their WTP to improve from one health state to another. Results: Subjects 
provided a range of responses to their time-trade-off from hope (“Cancer is curable 
/ Treatment may be effective”) to concerns of family burden and self-preservation 
(“Prefer to live as long as possible”). The most common reasons presented was 
being “Prefer to die than living with cancer” (43% of states) and “Financial burden 
to others / Prefer to save money for others” (19.3%). Older subjects (50+ years old; 
53.3%) and females (48.7%) more frequently stated being “Prefer to die than living 
with cancer”. Rural respondents stated “Prefer to live as long as possible” more 
frequently than urban respondents (19.6% vs 12.9%). Patients based their payments 
on their expectations of recovering (70.7%) and to relieve symptoms (16.0%). The 
general public also based their payments on the relief of symptoms (32.0%) followed 
by the desire to live longer (18.0%). ConClusions: Our study found that subjects 
were able to provide valid estimates from the time-trade-off and willingness-to-
pay. These rationales provide insights into how responses are formulated within 
an Asian country. Additional research will need to be conducted to compare these 
results to other Asian and Western countries.
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objeCtives: Breast cancer is the most commonly diagnosed malignancy worldwide. 
Our study aims at exploring Hungarian women’s relationship to screening tests with 
their socio-demographic data, their knowledge on the risk factors responsible for the 
formation of breast tumors, and the practical application of self-examination of the 
breast. Methods: Quantitative, cross-sectional, descriptive study was conducted in 
2013. Non-random, accidental sample included persons aged between 23and 65 with-
out a history of breast cancer. 160 self-administered questionnaires were distributed, 
of which 120 proved to be evaluated. χ 2-test was performed besides 95% probability 
(p< 0.05). Data analysis was performed with SPSS 20.0 programs. Results: 69.6% 
of the respondents have not participated in breast screening during their lifetime. 
The average age of the first presentation in mammographic screening accounted for 
43.08±7.74 years. Among women participating in screening 22.5% of the them come 
to screening yearly, 38.8% of them visit screening every two years, 10% of them come 
in 3 years, and 12.5% of them turn up even less frequently. We found no significant 
differences between the socio-demographic characteristics and the participation in 
screening (p> 0.05) 64.3% of the interviewed women performed self-examination on 
the breasts, but only 15.7% of the respondents performed it correctly, 5 days after 
menstruation. Eight pictures supported by text explanation were shown to dem-
onstrate self-examination in the questionnaire.17.39% of the women could estab-
lish the correct sequence. One or two errors were made by 45.22%, three or four 
errors were made by 16.52% of the respondents and 20% gave completely wrong 
sequence. ConClusions: It should be important to raise awareness in the screening 
process, emphasize the potential benefits, limitations, and possible adverse effects 
for all women and in particular the risk they may have if they fail to participate. In 
the long term, it is inevitable to develop responsible health behavior.
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objeCtives: Many challanges are experienced in the care of cancer patients like how 
to reach the painless condition and how to improve the quality of life. The intensity of 
